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A B S T R A C TObjectives: Health care decision making, assessment, and procure-
ment of medicines is a complex, human resource–demanding, and
time-consuming process. A thorough evaluation of all factors involved
is necessary to optimize the process. The objective of this study was
to describe and analyze the current stage of health technology
assessment (HTA) in Cyprus. Methods: Literature research and pri-
vate communication with all involved parties and competent author-
ity. Moreover, data, decisions, and recommendations of the Drug’s
Committee were used. Results: Cyprus is a latecomer in this ﬁeld.
HTA has entered a growing phase after the 2007 reform. It has not
reached its full potential, and the current state is applicable only to
the public sector, because of the nonexistence of a national health
system. Therefore, this poses both a great challenge and a greatsee front matter Copyright & 2013, International S
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1016/j.vhri.2013.06.016
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us.barrier considering maximization of the value of money spent and
health access equity. Conclusions: There is deﬁnitely enough space
and clear necessity for further dissemination, and early successes
indicate that steps should be taken toward the introduction of an HTA
procedure that will cover both private and public sectors. The
introduction of a national health system will further enhance the
uptake of HTA, optimize the process, and use the common knowledge
strategy for evidence-based decision making.
Keywords: Drug’s Committee, evaluation, HTA, pharmaceuticals,
private sector, public sector.
Copyright & 2013, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Health Care Sector in Cyprus
Currently in Cyprus, two fragmented systems run in a parallel,
overlapping, and competitive manner with clear disparities
among them: public sector and private sector. This situation is
caused by the absence of a national health system. The Ministry
of Health (MOH) is the provider, regulator, and payer of public
sector beneﬁciaries. Public health care is highly centralized, and
the policymaking process takes place at the macro (ministerial)
level. There are ﬁve major categories of beneﬁciaries [1] according
to income and employment status. It is essential to underline
that 85% of the total population is entitled to free public medical
care, without any direct or indirect contribution. As a result,
moral hazard [2] has been prominent and was expressed by
overuse and misuse of medicines in the pharmaceutical sector. In
contrast, private sector’s patients pay the full amount out of
pocket, unless they are covered by an optional private insurance.
Health care costs in Cyprus account for 6% of gross domestic
product [3], which pushes Cyprus to the European low segment.
The rate of increase in costs in the health care sector outpaces
almost all other European Union (EU) countries [4] primarily
because of the following reasons [5]:1. An aging population that has an increasing life expectancy,
with concurrent increased morbidity.2.oc
o c
entLack of prescribing control due to the nonexistence of an
interface management system. The system was launched in
2010, but it is still not fully operational.3. No direct contribution of beneﬁciaries—Exploitation of moral
hazard.4. Policy susceptible to colloquial evidence especially regarding
new expensive products.5. Pharmaceuticals in the private sector are regulated only at the
price level.6. There is a duplication of high-cost hospital services in Cyprus,
which have high running cost but are not fully utilized.7. The above remark is augmented by the low value of the public
sector perceived by beneﬁciaries. This was an undisputable
ﬁnding of a recent study [6] that examined the value for
money regarding beneﬁciaries of the public sector. Under the
hypothesis that all health care systems want to gain more
health for the same amount of money, the perceived value of
the health system was assessed. The most important ﬁnding
is presented in Fig. 1.8. Preventive programs are underfunded. Preventive programs
apply usually to beneﬁciaries, while the ﬁnancial burden of
many diseases is entirely shifted to the MOH.9. There are no quality indicators. As a result, the MOH cannot
assess any health policy, and consequently arbitrary decisions
are taken regarding abortion or carryover of them.iety for Pharmacoeconomics and Outcomes Research (ISPOR).
onﬂicts of interest with regard to the content of this article.
Programme, Open University of Cyprus, P.O. BOX 12794, 2252.
Fig. 1 – Estimated savings from free public health care by age per household member (as percentage of household income). For
beneﬁciaries to free public health care of the age group 30 to 50 years, “no perceptible beneﬁt is realized from access to free of
charge public medical care.” This partly explains the fact that although 85% of the total population is a beneﬁciary of free
medical care, Cyprus has one of the highest out-of-pocket contributions in the European Union, along with the higher prices
of the private sector.
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traits that make it quite hard to interpret and deﬁnitely tell it
apart from other products with regard to their market analysis.
The pharmaceutical market posseses an unrivalled demand and
supply feature. There is a three-tier demand structure in which
the recipient (patients) of the products consumes but has little, if
any at all, involvement in the decision-making process. More-
over, the prescriber of the product is perceived as the customer,
but does not consume the product. Another feature is that the
cost does not represent the production cost. This is quite
illustrative in generic products that have, in certain cases such
as in Italy, half of the original product’s price, and they are still
proﬁtable. The price of the product is set to offset the research
and development expenses and in certain cases, such as in
France, is set at a premium to reward innovation.
Governments worldwide and health agencies have applied
speciﬁc and strict legislation to the pharmaceutical market to
ensure that1. Life-saving products are available; health systems should not
be exploited by industry.2. Good manufacturing processes are safeguarded along
the way.3. The unique demand and supply does not hinder the control
role of health agencies regarding product availability [7].HTA in Cyprus
Many authors have described HTA in a detailed manner [8]. In
Cyprus, HTA appeared as a term of reference of the Drug’s
Committee in early 2000 as a tool to address uncontrolled
increase in expenditure through rationalization of the decision-
making process [9]. Terms of reference were updated and
enriched in 2007, allowing further ﬂexibility and introduction of
more complex and legally demanding schemes. HTA is per-
formed through the Drug’s Committee, which falls under the
MOH (Pharmaceutical Services). We must highlight the partic-
ipation of Health Insurance Organization in the StakeholderForum and the participation of Pharmaceuticals Services at the
Joint Action 2 of European Network of Health Technology
Assessment .
The successful use of tendering, however, led to signiﬁcantly
low prices for the public sector, which distorted the need for a
sustaining and rational decision-making process (Fig. 2).Goals of HTA in Cyprus
According to the terms of reference, HTA should reach the
following goals [9,10]:1. Constantly upgrade, change, and improve clinical guidelines.
Currently, guidelines exist in the majority of
therapeutic areas.2. Deﬁne performance indicators and assess effectiveness of
medicines.3. Limit the use of newly launched technologies to therapeutic
areas for which there is sufﬁcient documentation of efﬁcacy
and safety.4. Reevaluate high expenditure monopoly medicines that con-
tribute disproportionately to the overall cost.5. Categorize evidence deﬁcit in areas in which certain technol-
ogies are destined and ways to ﬁll this.6. Disinvestment.Criteria for Inclusion of a Medicine in the Formulary
The Drug’s Committee decides on the reimbursement (or not) of a
product. It assesses drug request on the basis of ﬁve main pillars:1. Prevalence and epidemiology of the disease (prioritization of
resource allocation).2. Comparative effectiveness according to common practice.
3. Economic evaluation, primarily budget impact analysis and to
a lesser degree substantial cost-effectiveness studies (no
inclusion of indirect data).
Fig. 2 – SWOT analysis of health technology assessment in Cyprus. Source: Authors approach. HTA, health technology
assessment; MOH, Ministry of Health; NHS, National Health System; SWOT, strength, weakness, opportunities, and threat;
WTP, willingness to pay.
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National Institute of Clinical Excellence.5. Existing competitive medicines in the formulary.
The breadth and quality of data are assessed. As in other small
countries, the goal is to foster best practices instead of developing
ones. Because assessment is a context-free and context-sensitive
issue [11], transferability of data may be ﬂawed because of1. Demographic heterogeneity.
2. Costs. Difference in pricing, reimbursement rates, and
between the negotiating power of health prices will lead to
cost divergence between countries.3. Health care practices/different efﬁciency factor between
health systems.4. Cultural differences and social values between different pop-
ulations [12].
The Committee assesses medicines on the basis of several
criteria (Table 1) [13]:
Health outcomes measures include cost per quality-adjusted
life-years, life-years gained, progression-free and overall survival,
and disease-speciﬁc measures such as Psoriasis Approach Severity
Index and American College of Rheumatology Index. The number
needed to treat approach was implemented in the assessment of
smoking cessation products. This was also implemented for
competitive medicines that have a signiﬁcant price difference (e.
g., different Anatomic Therapeutic Chemical 3 categories) in order
to enhance competition in the tendering process.
In 2007, the ministerial decision [13] enabled the formation of a
therapeutic algorithm based on the outcome of the tender. Ther-
apeutically equal products competed and instead of eliminating
the losers, these were designated as second- and third-line therapy,
respectively. This occurred in certain therapeutic categories forwhich there is enough documentation that tolerance to relevant
medicines is limited and therefore, there is strong possibility that
patients may need to switch treatment. The case of the anti–tumor
necrosis factor agents was a landmark because the contribution of
all stakeholders (MOH, physicians, and patients) to the HTA process
has led to a mutually beneﬁcial outcome, and as a result every year
the list for anti–tumor necrosis factor agents has still available slots.
Major therapeutic categories that got into this scheme include
aromatase inhibitors, adjuvant immunosuppressive treatment,
such as mycophenolic acid, antidepressants, antiepileptic agents,
and erythropoetins. Before the assessment, companies are
allowed to provide further supporting materials regarding the
efﬁcacy and estimated cost of their products, which adds to the
transparency of the process.
Another concern of the Drug’s Committee is the possible off-
label use of expensive products, due to the overuse of medicines
in Cyprus as addressed earlier. This may lead to a reduction in
health beneﬁts associated with the use of a product, due to the
uncertainty associated with its off-label use. Therefore, the risk of
off-label use is counterbalanced by the requirement of preap-
proval. This was the primary reason for the rejection of ranibi-
zumab, despite recommendations by the National Institute for
Health and Clinical Excellence [14].
HTA implementation has not always been very successful in
broadening the scope and in certain cases overlooked one
intrinsic factor, interrelation to health policy [15]. The MOH
implemented a public campaign to create awareness among the
public for the prevention of cervix cancer; however, the Drug’s
Committee did not approve the only available vaccine. Moreover,
as the complexity factor of the therapeutic regimen increases,
such as in immunosuppressive ones, assessment can be compli-
cated and lengthy. A prominent example was assessment of the
mammalian target of rapamycin inhibitors whose dosage is
highly personalized and budget impact of each product is
Table 1 – Criteria for assessment.
Criteria Importance Comments
Disease prevalence Major Easy to assess
Guidelines of the National Institute
for Health and Clinical Excellence
Major Transferability of data has to be checked for major
divergences
Efﬁcacy data Major Clinical effectiveness must be assessed
Budget impact analysis Dominant May conﬂict with cost-effectiveness approach
Off-label use Medium (unless speciﬁc trend
documented)
Difﬁcult to assess, may compromise actual medical need.
Interface management will address this issue
Cost-effectiveness Major (difﬁcult to apply for each
medicine a country-speciﬁc
study)
A basic economic analysis is performed
Impact on spending for other
medical interventions
Medium Incorporation of nonpharmaceutical interventions. Interface
management may enable control. Difﬁcult to assess
Source: Terms of Reference, Drug’s Committee.
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sive treatment.Prescription Guidelines and Preapprovals
The Drug’s Committee has successfully implemented controlled
prescription of certain medicines. The majority of guidelines specify
treatment line, exceptions, patient proﬁle, further requirements such
as serum marker levels, expected duration of treatment, and indica-
tion of failure. Statins were one of the most successful examples. The
introduction of prescription guidelines for statins (including preap-
proval for high-potency statins) concomitantly with the introduction
of generic simvastatin was successful in avoiding the “reallocation of
demand,” as observed in Belgium (2007–2011: Daily deﬁned dose
consumption increased by 52%, cost decreased by 48%).
Similar guidelines were elaborated for the prescription of all
oncology medicines, insulin glargine, rosiglitazone, cinacalcet,
and darbeopetin alpha. For the majority of these products, a
preapproval is also necessary, usually with the obligation for the
submission of relevant laboratory documentation. The details of
the patients are ﬁled.
Indication-based guidelines were elaborated for angiotensin II
receptor blockers. Different protocols were compiled for hyper-
tension, congestive heart failure, and diabetic nephropathy.
In oncology medicines with signiﬁcant uncertainty and high
cost, due to the lack of effectiveness data, the Drug’s Committee
has made exceptions for the compassionate use of cancer drugs
in a small target group population in which beneﬁts may not be
sufﬁciently captured. Criteria are as follows:1. Patient’s life expectancy is less than 24 months.
2. There is sufﬁcient data that the treatment will extend life for
at least an additional 3 months compared with current
treatment.3. There is no alternative treatment with equal effectiveness
available.4. The target group is a small patient population [16].Managed Entry Agreements in Cyprus
Risk sharing [17] has not been implemented and price volume
agreement has been applied only scarcely, mainly due because
of human resources required for monitoring. Pemetrexed gainedanother indication of malignant pleural mesothelioma,
in addition to the one existing for non–small cell lung cancer.
Because of comparative effectiveness among all available
treatments for non–small cell lung cancer, an approach was
set up that consisted of three scenarios. The prices incorpo-
rated expected efﬁcacy of the product and net beneﬁt for the
company.
The addition of a new indication of deferasirox and the
increase in the daily dose to 40 mg/kg led to the managed entry
agreement of dose capping agreement between Novartis and
the MOH. On the basis of this agreement, the MOH reimburses
daily doses up to 30 mg/kg (average 2160 mg daily per patient)
while additional dosage burdens the company. The company is
obliged to provide free goods to the MOH, based on dose agree-
ments. Currently, 38 patients are registered in this scheme, which
will last for 3 years, and data will be revised every 6 months to
check for deviations.Further Potential for HTA in the New Financial Era
Cyprus has recently signed a memorandum of understanding with
Troica (term used to deﬁne the committee consisting of the Interna-
tional Monetary Fund, the European Union, and the European Central
Bank) to secure a life-sustaining bailout of 10 billion euros. As Troica’s
primary target is to enhance the efﬁciency of governance, one
important prerequisite for the health sector is the implementation
of HTA for the 10 costlier pharmaceutical and medical equipment.
This provision will further leverage shift toward an integrated HTA
system, and several approaches are currently being considered, such
as the introduction of two HTA formats, according to the estimated
budget impact (light and full version), an approach currently imple-
mented in many countries such as The Netherlands [18].Challenges for HTA in Cyprus
The current product mix of these two fragmented markets does
not allow dissemination of policies in the private sector, neg-
atively affecting health equity. Moreover, the Drug’s Committee
should be authorized to act proactively regarding the assessment
of new medicines.
An important limitation is the lack of an ofﬁcial willingness-
to-pay threshold in Cyprus [19] regarding economic evaluation.
Finally, the conﬂicting role of the MOH, which in the case
of HTA, it assesses, appraises, and procures as well, is a
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appraisal.Discussion
HTA should be incorporated in the context of a general health
policy because health policy deﬁnes the optimum use of a
medicine to deliver superior results. Health policy should cover
both sectors because ultimately all chronic patients will be
beneﬁciary of the public sector and prevention of discrimination
must be pursued.
Incorporation of other stakeholders (university, patient asso-
ciations) may enrich the decision-making process and lead to a
context for more informative outcomes, diverting the conﬂicting
role of the MOH.
A detailed cost-effectiveness analysis must be implemented,
at least for the cost driver categories, which also needs to be
regulated with regard to technical parameters, such as time
horizon, modeling methods, discounting, and type of economic
evaluation (budget impact, cost-effectiveness analysis). This was
also recommended by the Internal Audit department of Cyprus
[20].
Uncertainty needs to be addressed in the context of HTA in all
its expressions because it affects the impact of the decision and
sensitivity analysis must cover a range of assumptions.
Because of the variety of statistical approaches such as
metanalysis or mixed treatment comparison, an accepted format
should be elaborated taking into consideration particularities of
certain therapeutic categories. Moreover, the rating of evidence is
crucial and we suggest that GRADE classiﬁcation should be
adapted because it provides an excellent grading of evidence [21].
The scope of the assessment should be broad and must be
able to compare interdisciplinary interventions (i.e., medical vs.
pharmaceutical interventions) [22,23].
The existing coverage system does not make provision for
different levels of reimbursement, because all diseases are
considered to have the same utility. Consequently, the reim-
bursement levels are the same for all diseases. A classiﬁcation of
strength of evidence will enable better forecasting, resource
allocation, and demand control.
We observed that reduction in the pharmaceutical growth
rate seems to have coincided with the introduction of HTA
methods; however, this has to be veriﬁed. The normalization of
the annual pharmaceutical growth rate to less than 3% is a good
ﬁrst sign and at least partially is attributed to HTA implementa-
tion, which is gaining ground in Cyprus [24], as seen in Table 2.
We must however interpret this reduction in the increase rate
with caution because Cyprus’s economy entered a prolonged
recession period in 2008 [25]; therefore, this reduction can be
attributed to a tighter control of expenditures, rather than to the









HTAs, health technology assessments.
Source: Annual Report of Ministry Of Health, 2010.The Drug’s committee evaluates each product only at request.
We believe that this leads to lack of symmetry of the system.
More importantly, this does not allow comparison among treat-
ments and does not elaborate an overall approach to a disease,
which could be achieved by assessing other intervention meth-
ods. Several therapeutic interventions run in parallel and com-
parative effectiveness has not been documented. Periodical
assessment of guidelines and disease management should be
established and also assessment of medicines by the Drug’s
Committee would minimize reactions from the industry and
subsequent exerted pressures.
Finally, newer approaches must be incorporated taking into
account clinical uncertainty. The introduction of risk-sharing meth-
ods, price volume agreements, and managed entry agreement will
further optimize the HTA context in Cyprus. HTA is emerging in
Cyprus’s health care sector. There is an imperative need, and the
current ﬁnancial era does support further dissemination. The small
size of the country andmarket fragmentation hinders its full uptake.
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